Your browser doesn't support javascript.
loading
Evaluation of the effects of a dasatinib-containing, self-emulsifying, drug delivery system on HT29 and SW420 human colorectal carcinoma cells, and MCF7 human breast adenocarcinoma cells.
Baghdadi, Rehab A; Abdalla, Ashraf N; Abourehab, Mohammed A S; Tulbah, Alaa S.
Afiliación
  • Baghdadi RA; Department of Pharmaceutical Sciences, College of Pharmacy, Umm Al-Qura University, Makkah, KSA.
  • Abdalla AN; Department of Pharmaceutical Sciences, College of Pharmacy, Umm Al-Qura University, Makkah, KSA.
  • Abourehab MAS; Department of Pharmaceutical Sciences, College of Pharmacy, Umm Al-Qura University, Makkah, KSA.
  • Tulbah AS; Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Minia University, Minia, Egypt.
J Taibah Univ Med Sci ; 19(4): 806-815, 2024 Aug.
Article en En | MEDLINE | ID: mdl-39170071
ABSTRACT
Background/

Aim:

Dasatinib (DS), a second-generation tyrosine kinase inhibitor, functions as a multi-target small-molecule drug via targeting various tyrosine kinases involved in neoplastic cell growth. DS inhibits cancer cell replication and migration, and induces tumor cell apoptosis in a variety of solid tumors. However, it is poorly soluble in water under some pH values. Therefore, the development of a DS-containing, self-emulsifying, drug delivery system (SeDDs) could help overcome these problems in treating cancer cells.

Methods:

Various SeDD formulations loaded with DS were developed with isopropyl myristate (oil phase), Labrafil (surfactant), and polyethylene glycol (co-surfactant). The physicochemical properties of the formulations were assessed according to droplet size, encapsulation efficiency, and in vitro drug release. The cytotoxicity of the formulations on the cancer cell lines HT29 and SW420 (human colorectal carcinoma), and MCF7 (human breast adenocarcinoma), in addition to MRC5 normal human fetal lung fibroblasts, was evaluated to assess selectivity.

Results:

The DS-SeDD formulation showed favorable particle size, encapsulation efficiency, and in vitro drug release. The anti-cancer potency of DS-SeDDs had greater cytotoxicity effects than pure DA on the three cancer cell lines, MCF7, HT29, and SW420l.

Conclusion:

The developed DS-SeDD formulations may potentially be an effective sustained drug delivery method for cancer therapy.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Taibah Univ Med Sci Año: 2024 Tipo del documento: Article Pais de publicación:
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Taibah Univ Med Sci Año: 2024 Tipo del documento: Article Pais de publicación: